Effects of Exercise or Taping on Pain, Function, Range of Motion, Strength and Kyphosis in Subacromial Pain Syndrome

August 31, 2025 updated by: Sevtap Günay

Effects of Adding Thoracic Extension Exercises or Thoracic Kinesio Taping to Shoulder Exercises on Pain, Function, Range of Motion, Strength, and Thoracic Kyphosis in Adults With Subacromial Pain Syndrome

Participants with subacromial pain syndrome underwent shoulder exercises. In addition to the exercises, group A received thoracic extension exercise and group B received kinesio taping. All exercises were performed five days per week for three weeks. Thoracic extension exercise was performed once a week and remained in place for 5 days. Evaluations were performed one to three days before and one to three days after the three-week exercise program.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Seventy-five adults with subacromial pain syndrome were randomized into three groups. Group A and Group B received thoracal extension exersice and thoracal kinesiotaping in addition to shoulder exercise, respectively, while Group C received only shoulder exercise. All exercises were performed five days a week for three weeks. Thoracal extension exercise was applied once a week and remained in place for 5 days. Assessments were conducted one to three days before and one to three days after the three-week exercise program. Shoulder pain intensity, pressure pain threshold (PPT) of the upper trapezius and pectoralis major, self-reported function and health status, active range of motion (AROM), and isometric strength of the shoulder were assessed.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
75

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
      • Izmir, Turkey (Türkiye)
        • Izmir Bakircay University Cigli Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Having shoulder pain for at least 6 weeks
  • Aggravation of shoulder pain with resisted shoulder movements

Exclusion Criteria:

  • Those with full-thickness rotator cuff rupture
  • Those who have had previous shoulder surgery
  • Those who have had cervical or thoracic spine surgery
  • Those with a history of inflammatory disease or cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Group A
In addition to shoulder exercises, thoracic extension exercises were performed.
Other: Shoulder exercises + Thoracic extension exercise
Shoulder exercises and thoracic extension exercises were performed 5 days a week for 3 weeks.
Active Comparator: Group B
In addition to shoulder exercises, kinesio taping was applied.
Other: Shoulder exercises + Thoracic kinesio taping
In addition to shoulder exercises, thoracic kinesio taping was applied. Shoulder exercises were performed 5 days a week for 3 weeks. TKT was applied once a week and remained in place for 5 days.
Active Comparator: Group C
Only shoulder exercises were performed.
Other: Shoulder exercises
Shoulder exercises were performed. They were performed 5 days a week for 3 weeks.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Shoulder function assessment
Time Frame: At the beginning and after 3 weeks
Disabilities of the Arm, Shoulder and Hand Questionnaire was used to assess the condition. It is a questionnaire used to evaluate upper extremity function status. The questionnaire consists of three sections, and the person marks the appropriate answer for each question on the Likert system with a score of 5 (1: no difficulty, 2: mild difficulty, 3: moderate difficulty, 4: extreme difficulty, 5: completely unable to do). According to the DASH questionnaire result; a result between 0-100 is obtained from each section.
At the beginning and after 3 weeks
Muscle strength assessment
Time Frame: At the beginning and after 3 weeks
Muscle strength will be measured with a digital hand dynamometer. Muscle strength measurements of the subjects' flexion, extension abduction, adduction, external and internal rotation movements will be made. The measurements made with the dynamometer will be based on the fine muscle test positions and method defined by Lovett. The tests will be repeated three times and at least one minute of rest will be given between repetitions. The highest of the 3 repetitions was accepted as the result.
At the beginning and after 3 weeks
Thoracic kyphosis assessment
Time Frame: At the beginning and after 3 weeks
For thoracic kyphosis measurement, inclinometers were placed at T1-T2 and T12-L1 to perform the evaluation.
At the beginning and after 3 weeks
Pressure pain threshold assessment
Time Frame: At the beginning and after 3 weeks
Pressure pain threshold measurement was measured with an algometer device. Algometers are a device that can be used to define pressure and pressure pain threshold. Upper trapezius and pectoralis major muscles were evaluated.
At the beginning and after 3 weeks
Quality of life assessment
Time Frame: At the beginning and after 3 weeks
Health-related quality of life (SF-36) was assessed with the questionnaire. It consists of 36 items in total and has eight sub-parameters. These eight sub-parameters consist of physical function, pain, social function, physical role limitations, mental health, emotional role limitations, vitality, and general health parameters. The sub-scales are scored between 0-100 and an increase of 26 points indicates an increase in the quality of life.
At the beginning and after 3 weeks
Pain intensity assessment
Time Frame: At the beginning and after 3 weeks
It was evaluated using a visual analog scale. The scale is between 0 and 10 points, and increasing numbers indicate increased pain intensity.
At the beginning and after 3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Sevtap Günay

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Sevtap GUNAY UCURUM, Assoc. Dr., Izmir Katip Çelebi University, Department of Physiotherapy and Rehabilitation
  • Principal Investigator: Müge KIRMIZI, dr. lecturer, Izmir Katip Çelebi University, Department of Physiotherapy and Rehabilitation
  • Study Chair: Ayşenur YUKSEL, PT, Department of Physiotherapy and Rehabilitation, Bakircay University Training and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 6, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 15, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 6, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 10, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 10, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 15, 2025

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 8, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 31, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • KatipCelebiUniversity

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings